US court allows Lupin, Zydus Life to expand Myrbetriq patent argument scope

Lupin and Zydus have more ammunition to defend their at-risk launch and it reduces their financial penalty risk, Axis Capital said.

Leave a Reply

Your email address will not be published. Required fields are marked *